The short answer
Usually, yes. Nothing on the labels rules out using both. GLP-1 medicines slow stomach emptying, which can affect pills, so physicians watch oral hormones, especially when the GLP-1 dose goes up. Hormone therapy is not a weight-loss treatment.
What the GLP-1 labels say about pills
Semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) slow how fast the stomach empties. The Zepbound label says this can affect the absorption of medicines taken by mouth, and it tells women on birth control pills to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase [1]. The Wegovy label asks that the effects of oral medicines be monitored [2].
Those warnings are about contraceptive pills, not menopause hormones. A 2026 review found that one tirzepatide dose lowered peak levels of a birth control pill’s hormones by 55% to 66%, and that no comparable data exist for the progestogens used in menopause. The authors called an effect biologically plausible but unproven, and most likely at the start and at each dose increase [3].
Why that matters most for progesterone
If you have a uterus, progesterone is there to protect its lining from estrogen. A dip in how much of an oral progesterone capsule is absorbed is the scenario physicians think about, because it would be silent. That is one reason some physicians favor estradiol through the skin, or a levonorgestrel IUD for the lining, in women on a GLP-1; read is a Mirena IUD enough progesterone?. Bleeding you did not expect is always worth reporting. More on progesterone.
If you also take birth control
In perimenopause many women still need contraception, and hormone therapy is not birth control [4]. On tirzepatide, the label’s advice applies directly: switch from a contraceptive pill to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase [1]. An IUD sidesteps the question and can also protect the uterus lining during hormone therapy.
What physicians may do differently
- Favor estradiol through the skin. A patch or gel does not depend on the stomach, so the label’s concern about oral medicines does not apply in the same way [1].
- Pay attention around dose increases. That is when any absorption effect is most likely [3].
- Ask about bleeding. It is the practical signal that the lining may not be fully protected.
- Keep the weight goals separate. Women who carry more weight may have more frequent and severe hot flashes [5], but the GLP-1 treats weight and the hormones treat symptoms.
Does hormone therapy change GLP-1 weight loss?
| Study | Who | Finding |
|---|---|---|
| Mayo Clinic records, semaglutide | 16 postmenopausal women on hormone therapy and 90 not | At 12 months, 16% vs 12% of body weight lost [6] |
| Menopause Society meeting, 2026 | About 2,400 women on semaglutide and 1,500 on tirzepatide | Hormone therapy was linked to more weight loss on semaglutide; on tirzepatide the difference was not statistically significant [7] |
| SURMOUNT trials, tirzepatide | Women grouped by reproductive stage | Weight loss was similar before, during and after menopause: 26%, 23% and 23%, against 2% to 3% on placebo [8] |
These are small or observational studies. The researcher who presented that study, quoted in the Menopause Society’s release, said weight loss is not a reason to start hormone therapy and that the findings need to be confirmed in prospective trials [7], and the Spanish Menopause Society says the link should not justify starting hormones only to add weight loss [9]. The reasons to take hormone therapy are still hot flashes, night sweats, sleep disrupted by them, and vaginal symptoms.
Every hormone option is on the menopause care page. If you are still having periods, read starting HRT in perimenopause.
VevaMD is a technology company, not a medical provider. Educational content only, not medical advice. A US-licensed physician decides whether any treatment fits you, and a prescription is not guaranteed. Compounded medications are prepared by state-licensed pharmacies for individual patients. They are not FDA-approved and have not been reviewed by FDA for safety, effectiveness or quality.
Sources
- Zepbound® (tirzepatide) prescribing information. Eli Lilly. DailyMed. Checked October 23, 2026.
- Wegovy® (semaglutide) prescribing information, revised June 2026. Novo Nordisk. DailyMed. Checked October 23, 2026.
- Viana DPDC, Invitti AL, Jacobsen L, Schor E. Tirzepatide and oral progestogens: a hypothesis-generating review. Maturitas. 2026;214:109116. Checked October 23, 2026.
- National Institute for Health and Care Excellence (NICE). Menopause: identification and management (NG23). Recommendations, updated April 2026. Checked October 23, 2026.
- National Institute on Aging (NIH). Hot flashes: what can I do? Checked October 23, 2026.
- Hurtado MD, Tama E, Fansa S, et al. Weight loss response to semaglutide in postmenopausal women with and without hormone therapy use. Menopause. 2024;31(4):266-274. Checked October 23, 2026.
- The Menopause Society. Hormone therapy may increase weight loss effectiveness of GLP-1s. Press release, 2026 Annual Meeting. Checked October 23, 2026.
- Tchang BG, et al. Body weight reduction in women treated with tirzepatide by reproductive stage: a post hoc analysis from the SURMOUNT program. Obesity. 2025;33(5):851-860. Checked October 23, 2026.
- Sánchez-Prieto M, et al. Incretin-based therapies in peri- and postmenopausal women with obesity: an expert position statement from the Spanish Menopause Society. Maturitas. 2026;213:109101. Checked October 23, 2026.